A functional peptide and its application in the preparation of products for non-therapeutic purposes that promote the transport and absorption of metal ions.

By chelating functional peptides with metal ions to improve intestinal absorption, the problem of low absorption efficiency of divalent metal ions in existing technologies has been solved, achieving efficient metal ion transport and absorption, and improving nutritional imbalance in the human body.

CN123106831APending Publication Date: 2026-11-17AUSNUTRIA DAIRY CHINA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611602598.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing dietary supplements and inorganic/organic metal supplements cannot effectively overcome intestinal environment interference and the influence of anti-nutritional factors, resulting in low absorption efficiency of divalent metal ions and difficulty in improving the current nutritional imbalance in the human body.

Method used

The method involves chelating functional peptides with metal ions to form chelates through coordination, thereby altering the peptide chain conformation, enhancing transmembrane transport capacity, and promoting intestinal absorption.

Benefits of technology

It improves the bioavailability of divalent metal ions, overcomes precipitation and interference from anti-nutritional factors, and achieves efficient metal ion transport and absorption.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106831A_ABST
    Figure CN123106831A_ABST
Patent Text Reader

Abstract

This invention provides a functional peptide and its application in the preparation of products for non-therapeutic purposes that promote the transport and absorption of metal ions. The functional peptide of this invention has at least one of the following amino acid sequences: EHVSSSEEPI, HVSSSEEPIN, MEHVSSSEEPI, MEHVSSSEEPINI. The above-mentioned functional peptides with specific amino acid sequences can chelate with metal ions through coordination to form functional peptide-metal ion chelates. The binding of metal ions can induce a conformational change in the functional peptide chain, transforming the peptide chain from a loose and disordered structure to a more regular spatial conformation. This conformational change enhances the transmembrane transport capacity of the chelate, promotes the penetration of the chelate through the intestinal epithelial cell membrane, thereby improving the intestinal absorption efficiency of metal ions, improving the bioavailability of metal ions, and overcoming the defects of free divalent metal ions such as easy precipitation, susceptibility to interference from dietary anti-nutritional factors, and poor absorption and utilization.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to biotechnology, and more particularly to a functional peptide and its use in the preparation of products for non-therapeutic purposes that promote the transport and absorption of metal ions. Background Technology

[0002] Divalent metal ions are essential trace elements for maintaining normal physiological functions in the human body. Their absorption and metabolic balance are crucial for ensuring human growth and development, physiological homeostasis, and preventing metabolic diseases, playing an irreplaceable role in human health. Among them, calcium (Ca) 2+ ), Zinc (Zn) 2+ ), magnesium (Mg) 2+ ), Fe 2+ These are four types of divalent metal ions that are in high demand by the human body and have core physiological functions. Each of them performs its own function and works together to maintain the body's normal life activities.

[0003] Specifically, calcium ions are the core mineral components of human bones and teeth, playing a crucial role in the entire life cycle of human growth and development, and participating in multiple metabolic regulation processes. Zinc ions dominate human intellectual development, immune system construction, and overall growth and metabolism, serving as a key trace element for ensuring immune system homeostasis and promoting physical development. Magnesium ions can activate various functional enzymes in the human body, not only participating in bone growth regulation but also precisely maintaining normal neuromuscular excitability and preventing neuromuscular dysfunction. Ferrous ions, as the core active components of hemoglobin and myoglobin, are the core carriers for oxygen transport and storage in the human body, directly supporting the body's blood circulation and tissue oxygen supply metabolism processes.

[0004] Currently, nutritional imbalances caused by insufficient intake and poor absorption of divalent metal ions are prevalent globally, significantly impacting human nutritional health and hindering normal development and metabolic homeostasis. Effective nutritional regulation and intervention are urgently needed. Divalent metal ions, as essential core trace elements, require sufficient and balanced intake and absorption to ensure healthy development, physiological metabolism, and immune regulation across all age groups. According to publicly available data from the World Health Organization, approximately 17% of the global population (about 1.1 billion people) suffers from varying degrees of zinc deficiency; over 27% experience insufficient iron intake and absorption; magnesium deficiency-related metabolic abnormalities have a prevalence rate as high as 40%; and uneven calcium intake and inefficient absorption affect all age groups. Therefore, conducting research on nutritional interventions related to the regulation of divalent metal ion absorption, improving the efficiency of trace element absorption, and balancing the body's nutritional metabolism are of significant practical importance for optimizing nutritional status and ensuring the physical and mental health of the entire population.

[0005] Current research indicates that the human small intestine is the core site for the absorption and transport of various divalent metal ions. However, the intestinal absorption mechanisms of different metal ions all have inherent defects and are easily interfered with by external factors, resulting in generally low bioavailability of metal ions. Specifically, calcium ions are prone to precipitation in the intestinal physiological environment, making them difficult to absorb effectively by intestinal epithelial cells and significantly reducing their bioavailability. The absorption of zinc ions is highly susceptible to anti-nutritional factors such as phytic acid in the diet, as well as the individual's health status and metabolic level, resulting in poor absorption stability and large fluctuations in efficiency. Magnesium ions are mainly absorbed in the jejunum and ileum of the small intestine through a combination of active transport and passive diffusion. Their absorption process is strictly regulated by various factors such as the body's calcium ion concentration and vitamin D content, resulting in a complex and easily imbalanced regulatory mechanism. The absorption of ferrous ions is mainly concentrated in the duodenum and upper small intestine. Intestinal pH, dietary components, vitamin C content, and the expression level of transmembrane transport proteins all directly affect their absorption and transport efficiency, making it difficult to achieve efficient absorption through conventional dietary supplementation.

[0006] Current conventional methods for supplementing divalent metal ions mainly involve dietary supplements and inorganic / organic ion supplements. However, these only achieve basic ion intake and cannot specifically address the problems of low intestinal absorption efficiency, susceptibility to interference, and poor bioavailability, thus failing to effectively improve the body's current state of metal ion deficiency and metabolic imbalance. Therefore, developing a product and solution that can effectively promote the efficient transport and absorption of metal ions has become an urgent technical problem to be solved in this field, possessing significant scientific research value and promising prospects for industrial application. Summary of the Invention

[0007] To address the limitations of existing dietary supplements and inorganic or organic metal supplements, which only achieve ion uptake but cannot overcome issues such as intestinal environment interference, anti-nutritional factors, and ion precipitation, this invention provides a functional peptide and its application in promoting metal ion transport and absorption. This invention utilizes a functional peptide to mediate Zn... 2+ Mg 2+ Fe 2+ Ca 2+ This invention improves the intestinal transport and absorption of metal ions, enhancing the bioavailability of various essential metal ions, especially divalent metal ions. It achieves synergistic regulation of the absorption of multiple key trace elements without simply increasing the dosage of metal ion supplementation. This invention enriches fundamental research on peptide-metal ion interactions, providing a novel technological pathway for developing highly absorbable trace element nutritional intervention products. It holds significant scientific, industrial, and public health value for improving the current imbalance of divalent metal ion nutrition and maintaining human growth, development, and physiological homeostasis.

[0008] This invention provides a functional peptide that promotes the transport and absorption of metal ions, wherein the functional peptide has at least one of the following amino acid sequences:

[0009] (1) EHVSSSEEPI;

[0010] (2) HVSSSEEPIN;

[0011] (3) MEHVSSSEEPI;

[0012] (4) MEHVSSSEEPINI.

[0013] The present invention provides an isolated polynucleotide, wherein the above-mentioned functional peptide is encoded.

[0014] The present invention provides a recombinant vector comprising the aforementioned polynucleotides.

[0015] The present invention provides a recombinant cell, wherein the recombinant vector described above is included, or the genome contains the polynucleotides described above.

[0016] This invention provides the use of the above-mentioned functional peptide, the above-mentioned polynucleotide, the above-mentioned recombinant vector, or the above-mentioned recombinant cell in the preparation of a product for non-therapeutic purposes that promotes the transport and absorption of metal ions.

[0017] In the applications described above, the metal ions include divalent metal ions.

[0018] In the applications described above, the metal ions include Zn 2+ Mg 2+ Fe 2+ Ca 2+ At least one of them.

[0019] This invention provides the application of the above-mentioned functional peptides, polynucleotides, recombinant vectors, or recombinant cells in the preparation of health food products.

[0020] As described above, the health food includes at least one of the following: foods that help boost immunity, improve bone density, and maintain bone and joint health.

[0021] This invention provides a functional peptide that promotes the transport and absorption of metal ions. This functional peptide has at least one of the following amino acid sequences: EHVSSSEEPI, HVSSSEEPIN, MEHVSSSEEPI, or MEHVSSSEEPINI. In this invention, the above-mentioned functional peptide with specific amino acid sequences can chelate with metal ions through coordination to form a functional peptide-metal ion chelate. The binding of metal ions can induce a conformational change in the functional peptide chain, transforming the peptide chain from a loose and disordered structure to a more regular spatial conformation. This conformational change enhances the transmembrane transport capacity of the chelate, promotes the penetration of the chelate through the intestinal epithelial cell membrane, thereby improving the intestinal absorption efficiency of metal ions, improving the bioavailability of metal ions, and overcoming the defects of free divalent metal ions such as easy precipitation, susceptibility to interference from dietary anti-nutritional factors, and poor absorption and utilization. Attached Figure Description

[0022] Figure 1 This is a graph showing the cell survival rate results under the intervention of casein hydrolysate in one embodiment of the present invention;

[0023] Figure 2 This is a Venn diagram of the upper membrane peptide and the lower membrane peptide in one embodiment of the present invention;

[0024] Figure 3 This is a statistical diagram of the number of peptide segments of the common peptide in one embodiment of the present invention;

[0025] Figure 4 In one embodiment of the present invention, peptide E and Zn 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0026] Figure 5 In one embodiment of the present invention, peptide E and Mg 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0027] Figure 6 In one embodiment of the present invention, peptide E and Fe 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0028] Figure 7 In one embodiment of the present invention, peptide E and Ca 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0029] Figure 8 In one embodiment of the present invention, peptide H and Zn 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0030] Figure 9 In one embodiment of the present invention, peptide H and Mg 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0031] Figure 10 In one embodiment of the present invention, peptide H and Fe 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0032] Figure 11 In one embodiment of the present invention, peptide H and Ca 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0033] Figure 12 In one embodiment of the present invention, peptide M1 and Zn 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0034] Figure 13 In one embodiment of the present invention, peptide M1 and Mg 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0035] Figure 14 In one embodiment of the present invention, peptide M1 and Fe 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0036] Figure 15 In one embodiment of the present invention, peptide M1 and Ca 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0037] Figure 16 In one embodiment of the present invention, peptide M2 ​​and Zn 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0038] Figure 17 In one embodiment of the present invention, peptide M2 ​​and Mg 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0039] Figure 18 In one embodiment of the present invention, peptide M2 ​​and Fe 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0040] Figure 19 In one embodiment of the present invention, peptide M2 ​​and Ca 2+ Scanning electron microscope images and energy dispersive spectroscopy (EDS) analysis of the chelates;

[0041] Figure 20 This invention relates to an embodiment of different incubation times and concentrations of peptide E and Zn. 2+ The results of transmembrane transport;

[0042] Figure 21 This invention relates to an embodiment of different incubation times and concentrations of peptide E and Mg. 2+ The results of transmembrane transport;

[0043] Figure 22 This invention relates to an embodiment of different incubation times and concentrations of peptide E and Fe. 2+ The results of transmembrane transport;

[0044] Figure 23 In one embodiment of the present invention, different incubation times and different concentrations of peptide E and Ca were used. 2+ The results of transmembrane transport;

[0045] Figure 24 This invention relates to an embodiment of different incubation times and concentrations of peptide H and Zn. 2+ The results of transmembrane transport;

[0046] Figure 25 This invention provides an embodiment with different incubation times and concentrations of peptide H and Mg. 2+ The results of transmembrane transport;

[0047] Figure 26 In one embodiment of the present invention, different incubation times and different concentrations of peptide H and Fe were used. 2+ The results of transmembrane transport;

[0048] Figure 27 In one embodiment of the present invention, different incubation times and different concentrations of peptide H and Ca were used. 2+ The results of transmembrane transport;

[0049] Figure 28 This invention relates to an embodiment of the use of different incubation times and concentrations of peptide M1 and Zn. 2+ The results of transmembrane transport;

[0050] Figure 29 In one embodiment of the present invention, different incubation times and different concentrations of peptide M1 and Mg were used. 2+ The results of transmembrane transport;

[0051] Figure 30 In one embodiment of the present invention, different incubation times and different concentrations of peptide M1 and Fe were used. 2+ The results of transmembrane transport;

[0052] Figure 31 In one embodiment of the present invention, different incubation times and different concentrations of peptide M1 and Ca were used. 2+ The results of transmembrane transport;

[0053] Figure 32 This invention relates to an embodiment of the use of different incubation times and concentrations of peptide M2 ​​and Zn. 2+ The results of transmembrane transport;

[0054] Figure 33In one embodiment of the present invention, different incubation times and different concentrations of peptide M2 ​​and Mg were used. 2+ The results of transmembrane transport;

[0055] Figure 34 In one embodiment of the present invention, different incubation times and different concentrations of peptide M2 ​​and Fe were used. 2+ The results of transmembrane transport;

[0056] Figure 35 In one embodiment of the present invention, different incubation times and different concentrations of peptide M2 ​​and Ca were used. 2+ The results of transmembrane transport;

[0057] in, Figure 4 , Figure 5 , Figure 6 and Figure 7 In the image, (a) represents the scanning electron microscope image of EHVSSSEEPI before chelation, (b) represents the scanning electron microscope image of EHVSSSEEPI-divalent metal ion chelate, (c) represents the energy dispersive spectroscopy (EDS) diagram of EHVSSSEEPI before chelation, and (d) represents the EDS diagram of EHVSSSEEPI-divalent metal ion chelate.

[0058] Figure 8 , Figure 9 , Figure 10 and Figure 11 In the image, (a) represents the scanning electron microscope image of HVSSSEEPIN before chelation, (b) represents the scanning electron microscope image of the HVSSSEEPIN-divalent metal ion chelate, (c) represents the energy dispersive spectroscopy (EDS) diagram of HVSSSEEPIN before chelation, and (d) represents the EDS diagram of the HVSSSEEPIN-divalent metal ion chelate.

[0059] Figure 12 , Figure 13 , Figure 14 and Figure 15 In the image, (a) represents the scanning electron microscope image of MEHVSSSEEPI before chelation, (b) represents the scanning electron microscope image of MEHVSSSEEPI-divalent metal ion chelate, (c) represents the energy dispersive spectroscopy (EDS) diagram of MEHVSSSEEPI before chelation, and (d) represents the EDS diagram of MEHVSSSEEPI-divalent metal ion chelate.

[0060] Figure 16 , Figure 17 , Figure 18 and Figure 19In the image, (a) represents the scanning electron microscope image of MEHVSSSEEPINI before chelation, (b) represents the scanning electron microscope image of MEHVSSSEEPINI-divalent metal ion chelate, (c) represents the energy dispersive spectroscopy (EDS) diagram of MEHVSSSEEPINI before chelation, and (d) represents the EDS diagram of MEHVSSSEEPINI-divalent metal ion chelate. Detailed Implementation

[0061] To enable those skilled in the art to better understand the present invention, the present invention will be further described in detail below. The specific embodiments listed below are merely descriptions of the principles and features of the present invention, and the examples are only for explaining the present invention and are not intended to limit the scope of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0062] The first aspect of this invention provides a functional peptide that promotes the transport and absorption of metal ions, wherein the functional peptide has at least one of the following amino acid sequences:

[0063] (1) EHVSSSEEPI;

[0064] (2) HVSSSEEPIN;

[0065] (3) MEHVSSSEEPI;

[0066] (4) MEHVSSSEEPINI.

[0067] The functional peptide EHVSSSEEPI (amino acid sequence shown in SEQ ID NO:1) is composed of ten amino acids linked by peptide bonds from the N-terminus to the C-terminus, with the amino acid sequence Glu-His-Val-Ser-Ser-Ser-Glu-Glu-Pro-Ile (EHVSSSEEPI). The functional peptide HVSSSEEPIN (amino acid sequence shown in SEQ ID NO:2) is also composed of ten amino acids linked by peptide bonds from the N-terminus to the C-terminus, with the amino acid sequence His-Val-Ser-Ser-Ser-Glu-Glu-Pro-Ile-Asn (HVSSSEEPIN). The functional peptide MEHVSSSEEPI (amino acid sequence shown in SEQ ID NO:3) is composed of eleven amino acids linked by peptide bonds from the N-terminus to the C-terminus, with the amino acid sequence being methionine-glutamic acid-histidine-valine-serine-serine-glutamic acid-glutamic acid-proline-isoleucine (Met-Glu-His-Val-Ser-Ser-Ser-Glu-Glu-Pro-Ile, MEHVSSSEEPI). The functional peptide MEHVSSSEEPINI (amino acid sequence shown in SEQ ID NO:4) is composed of thirteen amino acids linked by peptide bonds from the N-terminus to the C-terminus, with the amino acid sequence being methionine-glutamic acid-histidine-valine-serine-serine-glutamic acid-glutamic acid-proline-isoleucine-asparagine-isoleucine (Met-Glu-His-Val-Ser-Ser-Ser-Glu-Glu-Pro-Ile-Asn-Ile, MEHVSSSEEPINI). The above-mentioned functional peptides can be prepared using conventional methods in the field, as long as at least one of the above-mentioned amino acid sequences is obtained.

[0068] In this invention, the aforementioned functional peptides with specific amino acid sequences can chelate with metal ions through coordination to form functional peptide-metal ion chelates. The binding of metal ions can induce a conformational change in the functional peptide chain, transforming it from a loose, disordered structure into a more regular spatial conformation. This conformational change enhances the transmembrane transport capacity of the chelate, promoting its penetration through the intestinal epithelial cell membrane, thereby improving the intestinal absorption efficiency of metal ions, enhancing their bioavailability, and overcoming the defects of free divalent metal ions such as easy precipitation, susceptibility to interference from dietary anti-nutritional factors, and poor absorption and utilization. It should be understood that any functional peptide possessing at least one amino acid sequence from EHVSSSEEPI, HVSSSEEPIN, MEHVSSSEEPI, or MEHVSSSEEPINI, and capable of promoting metal ion transport and absorption, can be included in the technical solution of this invention.

[0069] A second aspect of the present invention provides an isolated polynucleotide, wherein the above-described functional peptide is encoded.

[0070] A third aspect of the present invention provides a recombinant vector comprising the aforementioned polynucleotides.

[0071] A fourth aspect of the present invention provides a recombinant cell, comprising the above-described recombinant vector, or having the above-described polynucleotides integrated into its genome.

[0072] Based on the amino acid sequence of the functional peptide provided by the present invention, those skilled in the art can obtain the polynucleotide sequence encoding the amino acid sequence according to conventional techniques in the art, and can also obtain a recombinant vector containing the polynucleotide sequence, thereby obtaining recombinant cells containing the polynucleotide sequence and / or the recombinant vector. It is understood that those skilled in the art, based on the known amino acid sequence of the functional peptide of the present invention, can obtain the polynucleotide encoding the amino acid sequence of the functional peptide, insert the polynucleotide into an expression vector to obtain a recombinant vector, and then transform the recombinant expression vector into host cells to obtain recombinant cells.

[0073] The fifth aspect of the present invention provides the use of the above-described functional peptide, the above-described polynucleotide, the above-described recombinant vector, or the above-described recombinant cell in the preparation of a product for non-therapeutic purposes that promotes the transport and absorption of metal ions.

[0074] Functional peptides can serve as carriers for the binding and delivery of divalent metal ions. Utilizing acidic amino acid residues and phosphorylation sites in their sequences, they form stable chelates with calcium, iron, zinc, magnesium, and other metals, thereby maintaining the solubility and dispersion of metal ions during processing, storage, and the gastrointestinal environment. This improves the efficiency of metal ion transport across the intestinal epithelium, thus enhancing the bioavailability of metal ions under complex dietary conditions. Polynucleotides, recombinant vectors, or recombinant cells can be used to efficiently prepare these functional peptides, ensuring stable sources and controllable quality, making them suitable for use in non-therapeutic products.

[0075] Furthermore, the metal ions include divalent metal ions. Preferably, the metal ions include Zn. 2+ Mg 2+ Fe 2+ Ca 2+ At least one of them.

[0076] The sixth aspect of the present invention provides the application of the above-mentioned functional peptide, the above-mentioned polynucleotide, the above-mentioned recombinant vector or the above-mentioned recombinant cell in the preparation of health food.

[0077] Furthermore, health foods can be those that help boost immunity, improve bone density, or help maintain bone and joint health.

[0078] It is understood that the present invention also provides a functional peptide-metal ion chelate, comprising a functional peptide and a metal ion; wherein the amino acid sequence of the functional peptide is selected from one of the following: EHVSSSEEPI, HVSSSEEPIN, MEHVSSSEEPI, MEHVSSSEEPINI; and the metal ion is selected from one of the following: Zn 2+ Mg 2+ Fe 2+ Ca 2+ .

[0079] The above-mentioned functional peptides may be Zn 2+ Mg 2+ Fe 2+ Ca 2+ This provides stable binding sites, allowing metal ions to exist in a chelated state. This reduces the risk of metal ions becoming free or precipitated in the gastrointestinal environment due to pH changes or interactions with components such as phytic acid and oxalic acid, resulting in more stable dispersibility and solubility, thus facilitating intestinal transport and absorption. Therefore, this chelate can serve as a metal ion delivery carrier in nutritional fortification and health foods, improving the bioavailability of various divalent metal ions under complex digestive conditions.

[0080] The technical solution of this application will be further explained below with reference to specific embodiments. Experimental methods in the following embodiments that do not specify specific conditions are generally performed under conventional conditions or as recommended by the manufacturer. Unless otherwise specified, all reagents used are commercially available or obtained through public channels.

[0081] Example 1

[0082] The lining of the human small intestine is composed of a densely packed epithelial barrier. The luminal side of these epithelial cells contains brush border membrane peptidases that degrade polypeptides. Therefore, nutrients within the intestinal lumen must withstand the hydrolysis by brush border membrane peptidases and penetrate this epithelial barrier to be absorbed into the bloodstream. This embodiment constructs a human clonal colon adenocarcinoma cell line (Caco-2) monolayer model to simulate the small intestinal lining in vitro. The upper layer simulates the luminal environment, and the lower layer simulates the basal side blood circulation environment. Active peptides resistant to brush border membrane peptidases and capable of being absorbed by the intestinal epithelium in intact peptide form are screened from casein hydrolysates. The specific procedures are as follows:

[0083] Caco-2 cells were treated with casein hydrolysate at different final concentrations (0.25 mg / mL, 0.5 mg / mL, 1 mg / mL, 2 mg / mL, and 4 mg / mL) for 24 h, and the cell viability of Caco-2 cells was measured. Specific results can be found in [link to results]. Figure 1 ( Figure 1 Different letters indicate significant differences (P < 0.05), while the same letter indicates no significant differences (P > 0.05). Figure 1 The results showed that when the casein hydrolysate concentration was ≤2.0 mg / mL, the cell viability of Caco-2 cells was above 80%, and the casein hydrolysate had no significant toxic effect on the activity of Caco-2 cells within this concentration range. Based on the above cell safety evaluation results, a casein hydrolysate concentration of 2 mg / mL was selected for subsequent transmembrane transport experiments.

[0084] A Caco-2 cell monolayer model was constructed using 12-well Transwell chambers (cultured to day 21, fully polarized, and with a TEER value > 250 Ω / cm). 2 2.0 mg / mL of casein hydrolysate was added to the upper layer of the monolayer, and after incubation for 2 h, the composition of peptides in the upper layer of the monolayer (referred to as upper layer peptides) and the composition of peptides in the lower layer of the monolayer (referred to as lower layer peptides) were analyzed by mass spectrometry.

[0085] Venn diagram analysis was performed on upper and lower membrane peptides to compare their categorization differences. (See details...) Figure 2 . Figure 2The study revealed 579 shared peptides between the upper and lower membrane layers. These peptides consist of a mixture of original hydrolyzed peptides from casein hydrolysates and derivative peptides generated by brush border membrane peptidase hydrolysis. The shared peptides suggest that these peptides possess the potential for transmembrane transport across the Caco-2 cell monolayer and can withstand brush border membrane peptidase hydrolysis, allowing for absorption into the bloodstream as intact peptides. There were 245 unique peptides in the upper membrane layer. Some of these peptides cannot be transported via peptide transporters, paracellular pathways, transcellular diffusion, or endocytosis, making them difficult for the intestinal epithelium to absorb. Others consist of short peptides and free amino acids newly generated by brush border membrane peptidase hydrolysis. There were 67 unique peptides in the lower membrane layer, most of which are derived from brush border membrane peptidase hydrolysis.

[0086] Further analysis revealed that the peptide range of the 579 shared peptides in the upper and lower layers of the Caco-2 cell monolayer membrane was 3-25, as detailed in [the specific details can be found in the original text]. Figure 3 . Figure 3 The results showed that 461 peptides had ≤15 amino acid residues, accounting for 79.62% of the total peptides. The transport capacity of peptides across the Caco-2 cell monolayer is related to the number of amino acid residues. Existing studies have confirmed that most bioactive peptides composed of 3-15 amino acids can be completely absorbed through the intestinal epithelium; while long peptides with more than 15 amino acid residues are more easily hydrolyzed by brush border membrane peptidases and are difficult to be absorbed by the intestine.

[0087] The above experimental results indicate that the small intestine exhibits selectivity in both the hydrolysis and transepithelial absorption of peptides; only peptides that are resistant to brush border membrane peptidase hydrolysis and can be absorbed by the intestine in intact peptide form (such as the aforementioned common peptides) can fully exert their biological activity in the body.

[0088] Example 2

[0089] Based on the experimental results of Example 1, the isoelectric point (pI) and net charge at pH 7 of the above-mentioned common peptides were analyzed using a peptide property calculation server. The specific results are shown in Table 1.

[0090] Table 1: Simulation Results

[0091]

[0092] Based on peptide length (<15 amino acid residues), isoelectric point, and net charge at pH 7, EHVSSSEEPI (hereinafter referred to as peptide E), number 3, HVSSSEEPIN (hereinafter referred to as peptide H), number 4, MEHVSSSEEPI (hereinafter referred to as peptide M1), and MEHVSSSEEPINI (hereinafter referred to as peptide M2) were selected as functional peptides for further research.

[0093] Example 3

[0094] Based on the experimental results of Example 2, this example uses scanning electron microscopy to determine the chelation of the above-mentioned functional peptides with divalent metal ions. The specific operation is as follows:

[0095] (1) Preparation of functional peptide samples and functional peptide-divalent metal ion chelate samples:

[0096] The above-mentioned peptides E, H, M1, and M2 were artificially synthesized to obtain functional peptide samples. Each functional peptide sample was dissolved in deionized water and stirred for 30 min until completely dissolved to prepare a functional peptide solution with a final concentration of 5 mg / mL.

[0097] ① Add CaCl2 powder slowly to the functional peptide solution at a mass ratio of 50:7 for the functional peptide solute to calcium chloride (CaCl2) while stirring magnetically to ensure complete dissolution of CaCl2; then add 250 mL of 20 mM Tris-HCl buffer, adjust the pH to 6.0, transfer to a constant temperature water bath, set the temperature to 40℃ and the stirring speed to 300 rpm, and continuously stir and chelate for 1 h to obtain the functional peptide-calcium chelate solution.

[0098] ② Add ZnSO4 to the functional peptide solution at a mass ratio of 1:1 (functional peptide solute to zinc sulfate (ZnSO4)) and stir magnetically to ensure uniform mixing. Then add 0.1 mol / L hydrochloric acid (HCl) solution to adjust the pH to 6.0, transfer to a constant temperature water bath, set the temperature to 60℃ and the stirring speed to 300 rpm, and continuously stir and chelate for 1 h to obtain the functional peptide-zinc chelate solution.

[0099] ③ Following the method in ②, only replace ZnSO4 with MgCl2·6H2O to obtain the functional peptide-magnesium chelate solution.

[0100] ④ Following the method in ②, only replace ZnSO4 with FeSO4·7H2O and add ascorbic acid to maintain the stability of ferrous iron (the molar ratio of ascorbic acid to FeSO4·7H2O is 2:1), and finally obtain the functional peptide-iron chelate solution.

[0101] The chelation solution was transferred to an ice-water bath for cooling, and anhydrous ethanol (volume ratio of anhydrous ethanol to chelation solution was 4:1) was added. After thorough mixing, the mixture was allowed to stand at 4°C for 4 h to promote the precipitation of functional peptide-divalent metal ion chelate. Subsequently, the mixture was centrifuged at 12000 rpm for 15 min at 4°C, the supernatant was discarded, the precipitate was collected, and the precipitate was freeze-dried to obtain the functional peptide-divalent metal ion chelate sample.

[0102] (2) Scanning electron microscopy (SEM) examination:

[0103] The microstructure and surface elemental composition of the above-mentioned functional peptide samples and functional peptide-divalent metal ion chelate samples were characterized using a scanning electron microscope (ZEISS GeminiSEM 300, Germany) equipped with energy-dispersive spectroscopy (EDS). The samples were uniformly dispersed on double-sided conductive adhesive on the sample stage, cleaned by high-purity nitrogen purging, and then sputter-coated with gold to enhance conductivity. They were then observed and images were acquired under a microscope (magnification 10000×). Further analysis of the elemental composition changes before and after the functional peptides chelated with divalent metal ions was performed using energy-dispersive spectroscopy.

[0104] (3) Results analysis:

[0105] EHVSSSEEPI (peptide E) and divalent metal ions (Zn) 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 4 EHVSSSEEPI and divalent metal ions (Mg 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 5 EHVSSSEEPI and divalent metal ions (Fe 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 6 EHVSSSEEPI and divalent metal ions (Ca 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 7 .exist Figure 4 , Figure 5 , Figure 6 and Figure 7 In the diagram, (a) and (c) represent the scanning electron microscope (SEM) image and energy dispersive spectroscopy (EDS) spectrum of EHVSSSEEPI before chelation, respectively; (b) and (d) represent the SEM image and EDS spectrum of the EHVSSSEEPI-divalent metal ion chelate, respectively. HVSSSEEPIN (peptide H) and divalent metal ion (Zn) 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 8 HVSSSEEPIN and divalent metal ions (Mg 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 9 HVSSSEEPIN and divalent metal ions (Fe 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 10 HVSSSEEPIN and divalent metal ions (Ca) 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 11 .exist Figure 8 , Figure 9 , Figure 10 and Figure 11In the diagram, (a) and (c) represent the scanning electron microscope (SEM) image and energy dispersive spectroscopy (EDS) spectrum of HVSSSEEPIN before chelation, respectively; (b) and (d) represent the SEM image and EDS spectrum of the HVSSSEEPIN-divalent metal ion chelate, respectively. MEHVSSSEEPIN (peptide M1) and divalent metal ion (Zn) 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 12 MEHVSSSEEPI and divalent metal ions (Mg 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 13 MEHVSSSEEPI and divalent metal ions (Fe 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 14 MEHVSSSEEPI and divalent metal ions (Ca 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 15 .exist Figure 12 , Figure 13 , Figure 14 and Figure 15 In the diagram, (a) and (c) represent the scanning electron microscope (SEM) image and energy dispersive spectroscopy (EDS) spectrum of MEHVSSSEEPI before chelation, respectively; (b) and (d) represent the SEM image and EDS spectrum of the MEHVSSSEEPI-divalent metal ion chelate, respectively. MEHVSSSEEPI (peptide M2) and divalent metal ion (Zn) 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 16 MEHVSSSEEPINI with divalent metal ions (Mg 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 17 MEHVSSSEEPINI with divalent metal ions (Fe 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 18 MEHVSSSEEPINI with divalent metal ions (Ca 2+ The scanning electron microscope image and energy dispersive spectroscopy (EDS) analysis diagram of the chelate are shown below. Figure 19 .exist Figure 16 , Figure 17 , Figure 18 and Figure 19 In the image, (a) and (c) represent the scanning electron microscope image and energy dispersive spectroscopy (EDS) diagram of MEHVSSSEEPINI before chelation, respectively, and (b) and (d) represent the scanning electron microscope image and EDS diagram of the MEHVSSSEEPINI-divalent metal ion chelate, respectively.

[0106] The scanning electron microscopy images above show that all unchelated functional peptide samples exhibit irregular but relatively smooth morphologies. However, upon chelation with any divalent metal ion, their microstructures undergo significant changes, characterized by denser particle stacking and a sharp increase in surface roughness, indicating that divalent metal ions effectively promote peptide aggregation. From a molecular mechanism perspective, active groups such as amino, carboxyl, and thiol groups in peptide chains can form weak aggregates through non-covalent interactions such as hydrogen bonding. The coordination effect of metal ions further enhances this process: after binding to amino acid residues, the metal masks hydrophilic groups, enhancing the hydrophobicity of the peptide chain, thereby driving intermolecular aggregation. Among these, Zn... 2+ It may also promote aggregation by regulating solution surface tension, enhancing intermolecular forces, and inducing anisotropic interactions.

[0107] The above energy dispersive spectroscopy (EDS) analysis results show that corresponding metal element signals were detected in all chelated samples, and the element contents were in a similar range (Zn approximately 11.88%-13.85%, Mg approximately 2.75%-4.38%, Fe approximately 4.30%-6.40%, Ca approximately 3.37%-6.24%). At the same time, the relative proportions of major elements such as C, O, and N also changed systematically, directly confirming that the above functional peptides successfully chelated with divalent metal ions, and that the elements were redistributed during the chelation process.

[0108] Example 4

[0109] Four divalent metal ions (Zn) were pre-evaluated using the CCK-8 assay. 2+ Mg 2+ Fe 2+ Ca 2+ The study investigated the cytotoxicity of four functional peptides (peptide E, peptide H, peptide M1, and peptide M2) on Caco-2 cells. Preliminary experimental results showed that functional peptide concentrations of 0.5 mg / mL or 1 mg / mL, and Zn... 2+ The concentration is 0.2 mM, Mg 2+ At a concentration of 1 mM, Fe 2+ The concentration is 100 μM, Ca 2+ At a concentration of 0.25 mg / mL, the survival rate of Caco-2 cells was greater than 90%, indicating good safety. The above concentration was selected for divalent metal ion transport experiments, and the specific procedures are as follows:

[0110] Select cells cultured up to day 21 that have completed polarization and have a TEER value > 250 Ω / cm. 2 The effects of four functional peptides on the transmembrane transport of four divalent metal ions were evaluated using a mature Caco-2 cell monolayer model. The samples to be tested were divided into ① a metal ion control group (0.2 mM Zn...). 2+ 1 mM Mg 2+100 μM Fe 2+ 0.25 mg / mL Ca 2+ ); ② 0.5 mg / mL functional peptide-divalent metal ion experimental group (0.5 mg / mL peptide E + 0.2 mM Zn) 2+ 0.5 mg / mL peptide E + 1 mM Mg 2+ 0.5 mg / mL peptide E + 100 μM Fe 2+ ,0.5 mg / mL Peptide E+0.25 mg / mL Ca 2+ 0.5 mg / mL peptide H + 0.2 mM Zn 2+ 0.5 mg / mL peptide H+ 1 mM Mg 2+ 0.5 mg / mL peptide H + 100 μM Fe 2+ ,0.5 mg / mL peptide H+0.25 mg / mL Ca 2+ 0.5 mg / mL peptide M1 + 0.2 mM Zn 2+ 0.5 mg / mL peptide M1 + 1 mM Mg 2+ 0.5 mg / mL peptide M1 + 100 μM Fe 2+ 0.5 mg / mL peptide M1 + 0.25 mg / mL Ca 2+ 0.5 mg / mL peptide M2 ​​+ 0.2 mM Zn 2+ 0.5 mg / mL peptide M2 ​​+ 1 mM Mg 2+ 0.5 mg / mL peptide M2 ​​+ 100 μM Fe 2+ ,0.5 mg / mL peptide M2+0.25 mg / mL Ca 2+ ); ③ 1 mg / mL functional peptide-divalent metal ion experimental group (1 mg / mL peptide E + 0.2 mM Zn) 2+ 1 mg / mL peptide E + 1 mM Mg 2+ 1 mg / mL peptide E + 100 μM Fe 2+ 1 mg / mL peptide E + 0.25 mg / mL Ca 2+ 1 mg / mL peptide H + 0.2 mM Zn 2+ 1 mg / mL peptide H+ 1 mM Mg 2+ 1 mg / mL peptide H + 100 μM Fe 2+ 1 mg / mL peptide H + 0.25 mg / mL Ca 2+ 1 mg / mL peptide M1 + 0.2 mM Zn 2+ 1 mg / mL peptide M1 + 1 mM Mg2 + 1 mg / mL peptide M1 + 100 μM Fe 2+ 1 mg / mL peptide M1 + 0.25 mg / mL Ca 2+ 1 mg / mL peptide M2 ​​+ 0.2 mM Zn 2+ 1 mg / mL peptide M2 ​​+ 1 mM Mg 2+ 1 mg / mL peptide M2 ​​+ 100 μM Fe 2+ 1 mg / mL peptide M2 ​​+ 0.25 mg / mL Ca 2+ The solute of the sample to be tested was dissolved in Hanks' balanced salt solution (HBSS), and the final concentration was adjusted to the aforementioned set value to obtain the sample solution. 0.5 mL of the sample solution and 1.5 mL of preheated HBSS buffer were added to the upper layer (AP side) of the Caco-2 cell monolayer membrane model. The mixture was incubated at 37°C and 5% CO2 for 2 h. At different time points (30 min, 60 min, 90 min, 120 min), 1 mL of culture medium was collected from the lower layer (BL side) of the Caco-2 cell monolayer membrane model as the test sample. An equal volume of freshly preheated HBSS buffer was immediately added to the BL side to maintain a constant volume and level liquid levels on both sides of the chamber, eliminating the interference of hydrostatic pressure on the transport results. Based on the obtained test sample, the metal ion content was detected by atomic absorption spectrometry. The calculation formula is as follows:

[0111]

[0112] In the formula B n This indicates the concentration of divalent ions transported on the BL side of each well at different time points (30 min, 60 min, 90 min, 120 min); 1.5 is a constant representing 1.5 mL of HBSS buffer on the BL side; A n The concentration of divalent ions on the BL side of each well (at different time points of 30 min, 60 min, 90 min, and 120 min) represents the concentration of divalent ions at different time points; n is an independent variable of 1, 2, 3, or 4, representing time points of 30, 60, 90, and 120 min, respectively.

[0113] Under different incubation times and different concentrations of peptide E, four divalent metal ions (Zn) were observed. 2+ Mg 2+ Fe 2+ Ca 2+ The transmembrane transport of ) can be seen respectively. Figure 20 , Figure 21 , Figure 22 and Figure 23 ( Figure 20-23Different letters indicate significant differences (P < 0.05), while the same letter indicates no significant differences (P > 0.05). Figure 20-23 The results showed that, compared with the metal ion control group, the 0.5 mg / mL peptide E-divalent metal ion experimental group and the 1 mg / mL peptide E-divalent metal ion experimental group had a greater effect on Zn under different incubation times. 2+ Mg 2+ Fe 2+ Ca 2+ The transport capacity of all Zn ions was significantly increased (p < 0.05); and the promoting effect of peptide E on metal ion transport showed a clear concentration- and time-dependent effect. When the peptide E concentration reached 1 mg / mL and the incubation time reached 120 min, the transport capacity of all ions reached its peak, Zn 2+ The concentration of Mg was 3.323 ± 0.210 μg / well. 2+ The concentration of Fe was 5.213 ± 0.220 μg / well. 2+ The concentration was 0.784 ± 0.009 μg / well, Ca 2+ The value was 26.770 ± 0.190 μg / well.

[0114] Under different incubation times and different concentrations of peptide H, four divalent metal ions (Zn) were subjected to different treatment conditions. 2+ Mg 2+ Fe 2+ Ca 2+ The transmembrane transport of ) can be seen respectively. Figure 24 , Figure 25 , Figure 26 and Figure 27 ( Figure 24-27 Different letters indicate significant differences (P < 0.05), while the same letter indicates no significant differences (P > 0.05). Figure 24-27 The results showed that, compared with the metal ion control group, the 0.5 mg / mL peptide H-divalent metal ion experimental group and the 1 mg / mL peptide H-divalent metal ion experimental group had a greater effect on Zn under different incubation times. 2+ Mg 2+ Fe 2+ Ca 2+ The transport capacity of all Zn ions was significantly increased (p < 0.05); and the promoting effect of peptide H on metal ion transport showed a clear concentration- and time-dependent effect. When the peptide H concentration reached 1 mg / mL and the incubation time reached 120 min, the transport capacity of all ions reached its peak, with Zn being the most abundant. 2+ The concentration was 3.090 ± 0.070 μg / well, Mg 2+ The concentration was 4.270 ± 0.062 μg / well, Fe 2+ The concentration was 0.623 ± 0.008 μg / well, Ca2+ The value was 28.500 ± 0.760 μg / well.

[0115] Under different incubation times and different concentrations of peptide M1, four divalent metal ions (Zn) were observed. 2+ Mg 2+ Fe 2+ Ca 2+ The transmembrane transport of ) can be seen respectively. Figure 28 , Figure 29 , Figure 30 and Figure 31 ( Figure 28-31 Different letters indicate significant differences (P < 0.05), while the same letter indicates no significant differences (P > 0.05). Figure 28-31 The results showed that, at different incubation times, compared with the metal ion control group, the 0.5 mg / mL peptide M1-divalent metal ion experimental group and the 1 mg / mL peptide M1-divalent metal ion experimental group had a greater effect on Zn. 2+ Mg 2+ Fe 2+ Ca 2+ The transport capacity of all ions was significantly increased (p < 0.05); and the promoting effect of peptide M1 on metal ion transport showed a clear concentration- and time-dependent effect. When the peptide M1 concentration reached 1 mg / mL and the incubation time reached 120 min, the transport capacity of all ions reached its peak, Zn 2+ The concentration was 2.946 ± 0.072 μg / well, Mg 2+ The concentration of Fe was 4.667 ± 0.081 μg / well. 2+ The concentration was 0.619 ± 0.009 μg / well, Ca 2+ The value was 17.210 ± 0.350 μg / well.

[0116] Under different incubation times and different concentrations of peptide M2, four divalent metal ions (Zn) were observed. 2+ Mg 2+ Fe 2+ Ca 2+ The transmembrane transport of ) can be seen respectively. Figure 32 , Figure 33 , Figure 34 and Figure 35 ( Figure 32-35 Different letters indicate significant differences (P < 0.05), while the same letter indicates no significant differences (P > 0.05). Figure 32-35 The results showed that, compared with the metal ion control group, the 0.5 mg / mL peptide M2-divalent metal ion experimental group and the 1 mg / mL peptide M2-divalent metal ion experimental group had a greater effect on Zn under different incubation times. 2+ Mg 2+ Fe2+ Ca 2+ The transport capacity of all ions was significantly increased (p < 0.05); and the promoting effect of peptide M2 ​​on metal ion transport showed a clear concentration- and time-dependent effect. When the peptide M2 ​​concentration reached 1 mg / mL and the incubation time reached 120 min, the transport capacity of all ions reached its peak, Zn 2+ The concentration of Mg was 3.323 ± 0.210 μg / well. 2+ The concentration of Fe was 5.213 ± 0.220 μg / well. 2+ The concentration was 0.784 ± 0.009 μg / well, Ca 2+ The value was 20.790 ± 0.660 μg / well.

[0117] In summary, the four functional peptides (EHVSSSEEPI, HVSSSEEPIN, MEHVSSSEEPI, and MEHVSSSEEPINI) provided by this invention can resist the hydrolytic action of intestinal peptidases and are transported across the intestinal barrier to the bloodstream in the form of intact peptide fragments for absorption by the body. These functional peptides can also react with various divalent metal ions (Zn...). 2+ Mg 2+ Fe 2+ Ca 2+ Chelation occurs, thereby promoting the transmembrane transport of divalent metal ions from the intestinal barrier to the blood and their absorption by the body. At the same time, this transmembrane transport exhibits a clear concentration-dependent and time-dependent characteristic.

[0118] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A functional peptide that promotes the transport and absorption of metal ions, characterized in that, The functional peptide has at least one of the following amino acid sequences: (1) EHVSSSEEPI; (2) HVSSSEEPIN; (3) MEHVSSSEEPI; (4) MEHVSSSEEPINI.

2. An isolated polynucleotide, characterized in that, Encoding the functional peptide as described in claim 1.

3. A recombinant vector, characterized in that, Includes the polynucleotide described in claim 2.

4. A recombinant cell, characterized in that, Includes the recombinant vector of claim 3, or the polynucleotide of claim 2 integrated into the genome.

5. The use of the functional peptide of claim 1, the polynucleotide of claim 2, the recombinant vector of claim 3, or the recombinant cell of claim 4 in the preparation of a product for non-therapeutic purposes that promotes the transport and absorption of metal ions.

6. The application according to claim 5, characterized in that, The metal ions include divalent metal ions.

7. The application according to claim 5 or 6, characterized in that, The metal ions include Zn. 2+ Mg 2+ Fe 2+ Ca 2+ At least one of them.

8. The use of the functional peptide of claim 1, the polynucleotide of claim 2, the recombinant vector of claim 3, or the recombinant cell of claim 4 in the preparation of health food.

9. The application according to claim 8, characterized in that, The health food products mentioned include those that help boost immunity, improve bone density, or maintain bone and joint health.